We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Desmopressin and Dexamethasone Adjunctive Treatment for Leptospirosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00592566
Recruitment Status : Terminated (Numbe of eligible patients has been decreased over time.)
First Posted : January 14, 2008
Last Update Posted : January 14, 2008
Sponsor:
Collaborator:
Information provided by:

Study Description
Brief Summary:

Background: Pulmonary involvement in leptospirosis has been reported to be on the increase and is emerging as the main cause of death due to leptospirosis in many countries, including Thailand.

Methods: A prospective randomized controlled trial of desmopressin or high dose dexamethasone as adjunctive therapy in patients with suspected pulmonary hemorrhage associated with leptospirosis was conducted between July 2003 and October 2006 at 5 hospitals in Thailand.


Condition or disease Intervention/treatment Phase
Leptospirosis Drug: Dexamethasone, desmopressin Phase 2 Phase 3

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 64 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Randomized Controlled Trial of Desmopressin, and Dexamethasone as Adjunctive Therapy in Patients With Pulmonary Hemorrhage Associated With Leptospirosis
Study Start Date : July 2003
Primary Completion Date : October 2006
Study Completion Date : October 2006


Arms and Interventions

Arm Intervention/treatment
No Intervention: 1
Standard supportive care
Experimental: 2
Dexamethasone treatment
Drug: Dexamethasone, desmopressin
200 mg of dexamethasone IV infusion OD for 3 days or 0.3 microgram/ kg of desmopressin in 50 ml of saline, as a 30- minute infusion
Other Name: Minirin
Experimental: 3
Desmopressin treatment
Drug: Dexamethasone, desmopressin
200 mg of dexamethasone IV infusion OD for 3 days or 0.3 microgram/ kg of desmopressin in 50 ml of saline, as a 30- minute infusion
Other Name: Minirin


Outcome Measures

Primary Outcome Measures :
  1. Survival [ Time Frame: during in hospital admission ]

Secondary Outcome Measures :
  1. Days of mechanical ventilation [ Time Frame: during hospital admission ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years to 90 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adult patients (> 14 years) with suspected severe leptospirosis
  • patients who presented with acute fever (oral temperature more than 38.00 C for <15 days) in the absence of an obvious focus of infection
  • In the opinion of the attending physician might have pulmonary hemorrhage (i.e. history of hemoptysis, and/ or bilateral nodular or air space infiltration).

Exclusion Criteria:

  • pregnant or breastfeeding
  • those with history of bleeding disorder
  • those who had underlying diseases such as chronic liver disease, diabetes mellitus
  • those who received diuretic or glucocorticoid
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00592566


Locations
Thailand
Loei Hospital
Mueng, Loei Province, Thailand, 45000
Sponsors and Collaborators
Mahidol University
Thailand Research Fund
Investigators
Principal Investigator: Kanigar Niwattayakul, MD Loei Hospital, Loei, Thailand:
Study Chair: Yupin Suputtamongkol, MD Mahidol University
More Information

Responsible Party: Prof. Yupin Suputtamongkol, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
ClinicalTrials.gov Identifier: NCT00592566     History of Changes
Other Study ID Numbers: DDP2003
RDG4630213
First Posted: January 14, 2008    Key Record Dates
Last Update Posted: January 14, 2008
Last Verified: December 2007

Keywords provided by Mahidol University:
Severe leptospirosis
Pulmonary hemorrhage

Additional relevant MeSH terms:
Leptospirosis
Weil Disease
Gram-Negative Bacterial Infections
Bacterial Infections
Spirochaetales Infections
Dexamethasone acetate
Dexamethasone
BB 1101
Deamino Arginine Vasopressin
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hemostatics
Coagulants
Antidiuretic Agents
Natriuretic Agents